共同药业 reported revenue of ¥0.35B for the period ended 2026-06-30, +14.5% year on year. Net income was ¥-0.04B, a -11.1% net margin on a 14.1% gross margin. The largest revenue line is 自产 at 93% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.35B | +14.5% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥-0.04B | — |
| Net income | ¥-0.04B | — |
| Gross margin | 14.1% | Net margin -11.1% |
| Revenue Q/Q | +13.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 自产 | ¥0.32B | 93.4% |
| 非自产 | ¥0.02B | 6.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.30B | 85.9% |
| R&D | ¥0.03B | 8.5% |
| SG&A | ¥0.03B | 8.8% |
| Tax & other | ¥0.00B | 0.2% |
| Item | Amount |
|---|---|
| Total assets | ¥2.90B |
| Total liabilities | ¥2.03B |
| Shareholders' equity | ¥0.87B |
| Equity / assets | 30.0% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | -59% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
晓鸣股份 ・ 格林精密 ・ 恒帅股份 ・ 华绿生物 ・ 博亚精工 ・ 万辰集团 ・ 立高食品 ・ 商络电子 ・ 达瑞电子 ・ 深圳瑞捷 ・ 东箭科技 ・ 华利集团
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies